This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor.—Now that tumor biology has become an accepted part of otolaryngology-head and neck surgery research, more tissue cultures of both benign and malignant cells are being reported regularly. A problem is worsening with the reporting of names of cell lines that often do not give any information about the site of origin, whether the culture was from metastases or was primary, or whether it relates to other tissue cultures such as fibroblast or other malignant cells. The norm for protection of patient anonymity no longer allows names such as HeLa, and names such as HEp-2 or FaDu tell nothing about the specific tissue from which the cells derive or their biologic activity. Similarly detailed descriptions of related tissues such as those from primary metastases or special subclones of cells that could be derived in tissue culture have no uniform description. We, therefore, propose the following nomenclature be
RICHTSMEIER WJ, CAREY TE. Rationalized Nomenclature for Head and Neck Carcinomas. Arch Otolaryngol Head Neck Surg. 1987;113(12):1339–1340. doi:10.1001/archotol.1987.01860120085018